<p>StockNews.com 的研究分析師在週日發佈的報告中開始覆蓋 Cytosorbents（NASDAQ:CTSO - 獲取免費報告）的股票。該經紀公司對這家醫療研究公司的股票設定了 “持有” 評級。</p>
<p>其他幾位股票分析師最近也對 CTSO 發佈了報告。D. Boral Capital 在週五的研究報告中重申了 “買入” 評級，並對 Cytosorbents 的股票設定了 10.00 美元的目標價。HC Wainwright 在 11 月 11 日的研究報告中重申了 “中性” 評級，並對 Cytosorbents 的股票設定了 1.00 美元的價格目標。兩位研究分析師對該股票給予了持有評級，兩位給予了買入評級，一位給予了強烈買入評級。根據 MarketBeat.com 的數據，該公司的平均評級為 “適度買入”，共識價格目標為 4.67 美元。</p>
<p><strong>獲取我們對 CTSO 的最新分析</strong></p>
<h2>Cytosorbents 股票上漲 1.8%</h2>
<p>Cytosorbents 股票在週五開盤價為 0.94 美元。Cytosorbents 的 52 周低點為 0.70 美元，52 周高點為 1.59 美元。該公司的市值為 5121 萬美元，市盈率為 -2.60，貝塔值為 0.58。該公司的 50 日移動平均價格為 0.92 美元，200 日移動平均價格為 1.02 美元。公司的速動比率為 1.58，流動比率為 1.97，債務與股本比率為 1.06。</p>
<h2>機構資金流入和流出</h2>
<p>一些對沖基金和其他機構投資者最近對 CTSO 的持倉進行了調整。Atomi Financial Group Inc. 在第三季度收購了 Cytosorbents 的新頭寸，價值 51,000 美元。Geode Capital Management LLC 在第三季度增加了對 Cytosorbents 股票的持股，增幅為 7.5%。Geode Capital Management LLC 目前擁有 467,058 股該醫療研究公司的股票，價值 701,000 美元，此前在上個季度又購買了 32,415 股。最後，Sargent Investment Group LLC 在第二季度將其在 Cytosorbents 股票中的持倉提高了 4.9%。Sargent Investment Group LLC 目前擁有 1,433,500 股該醫療研究公司的股票，價值 1,008,000 美元，此前在上個季度又購買了 67,181 股。對沖基金和其他機構投資者持有該公司 32.87% 的股票。</p>
<h2>Cytosorbents 公司簡介</h2>
<p>(獲取免費報告)</p>
<p>Cytosorbents Corporation 從事醫療設備的研究、開發和商業化，其血液淨化技術平台結合了專有的吸附劑和多孔聚合物技術，業務遍及美國、德國及國際市場。其旗艦產品為 CytoSorb，一種用於膿毒症治療的體外細胞因子吸附器，作為輔助治療，適用於其他重症護理應用、預防和治療圍手術期併發症，以及維持或增強從供體處採集的實質器官的質量以進行器官移植；並提供 VetResQ，一種用於動物膿毒症、胰腺炎和其他危重疾病的輔助治療設備。</p>
<h2>精選故事</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Cytosorbents</li>
<li>為什麼投資高收益分紅股票？</li>
<li>量子機會：Skywater Technology 的長期潛力</li>
<li>醫療保健股票解析：為什麼你可能想要投資</li>
<li>Nebius Group：人工智能基礎設施的新星</li>
<li>除了喝咖啡，還有 3 種投資咖啡的方法</li>
<li>MarketBeat 週迴顧 – 12/30 - 1/03</li>
</ul>
<p><em>此即時新聞提醒由敍事科學技術和來自 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送郵件至 contact@marketbeat.com.</em></p>
<p>→ 特朗普故意推動此加密貨幣上漲（來自 Crypto 101 Media）（廣告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMTA4Ng?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMTA4Ng"/></p>
<h2>你現在應該投資 1,000 美元在 Cytosorbents 嗎？</h2>
<p>在你考慮 Cytosorbents 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前立即購買……而 Cytosorbents 並不在名單上。</p>
<p>雖然 Cytosorbents 目前在分析師中有 “買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

CTSO

<p>Cytosorbents（納斯達克代碼：CTSO）獲得了 StockNews.com 的 “持有” 評級，該機構對該股票進行了覆蓋。其他分析師的意見各不相同，D. Boral Capital 給予 “買入” 評級，目標價為 10 美元，而 HC Wainwright 則設定了中性評級，目標價為 1 美元。該股票開盤價為 0.94 美元，52 周區間為 0.70 美元至 1.59 美元。機構投資者持有該公司 32.87% 的股份，該公司專注於血液淨化的醫療設備</p>

<p>Research analysts at StockNews.com initiated coverage on shares of Cytosorbents (NASDAQ:CTSO - Get Free Report) in a report released on Sunday. The brokerage set a &#34;hold&#34; rating on the medical research company's stock.</p>
<div class="lb-trans"><p>StockNews.com 的研究分析師在週日發佈的報告中開始覆蓋 Cytosorbents（NASDAQ:CTSO - 獲取免費報告）的股票。該經紀公司對這家醫療研究公司的股票設定了 “持有” 評級。</p>
</div><p>Several other equities analysts have also recently issued reports on CTSO. D. Boral Capital reiterated a &#34;buy&#34; rating and issued a $10.00 target price on shares of Cytosorbents in a research note on Friday. HC Wainwright reiterated a &#34;neutral&#34; rating and issued a $1.00 price objective on shares of Cytosorbents in a research report on Monday, November 11th. Two research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $4.67.</p>
<div class="lb-trans"><p>其他幾位股票分析師最近也對 CTSO 發佈了報告。D. Boral Capital 在週五的研究報告中重申了 “買入” 評級，並對 Cytosorbents 的股票設定了 10.00 美元的目標價。HC Wainwright 在 11 月 11 日的研究報告中重申了 “中性” 評級，並對 Cytosorbents 的股票設定了 1.00 美元的價格目標。兩位研究分析師對該股票給予了持有評級，兩位給予了買入評級，一位給予了強烈買入評級。根據 MarketBeat.com 的數據，該公司的平均評級為 “適度買入”，共識價格目標為 4.67 美元。</p>
</div><p><strong>Get Our Latest Analysis on CTSO</strong></p>
<div class="lb-trans"><p><strong>獲取我們對 CTSO 的最新分析</strong></p>
</div><h2>Cytosorbents Stock Up 1.8 %</h2>
<div class="lb-trans"><h2>Cytosorbents 股票上漲 1.8%</h2>
</div><p>Cytosorbents stock opened at $0.94 on Friday. Cytosorbents has a 52 week low of $0.70 and a 52 week high of $1.59. The firm has a market cap of $51.21 million, a price-to-earnings ratio of -2.60 and a beta of 0.58. The business's 50-day moving average price is $0.92 and its 200 day moving average price is $1.02. The company has a quick ratio of 1.58, a current ratio of 1.97 and a debt-to-equity ratio of 1.06.</p>
<div class="lb-trans"><p>Cytosorbents 股票在週五開盤價為 0.94 美元。Cytosorbents 的 52 周低點為 0.70 美元，52 周高點為 1.59 美元。該公司的市值為 5121 萬美元，市盈率為 -2.60，貝塔值為 0.58。該公司的 50 日移動平均價格為 0.92 美元，200 日移動平均價格為 1.02 美元。公司的速動比率為 1.58，流動比率為 1.97，債務與股本比率為 1.06。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><p>A number of hedge funds and other institutional investors have recently made changes to their positions in CTSO. Atomi Financial Group Inc. acquired a new position in Cytosorbents during the third quarter worth $51,000. Geode Capital Management LLC increased its stake in shares of Cytosorbents by 7.5% during the third quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company's stock worth $701,000 after purchasing an additional 32,415 shares in the last quarter. Finally, Sargent Investment Group LLC raised its position in shares of Cytosorbents by 4.9% during the 2nd quarter. Sargent Investment Group LLC now owns 1,433,500 shares of the medical research company's stock worth $1,008,000 after purchasing an additional 67,181 shares during the last quarter. Hedge funds and other institutional investors own 32.87% of the company's stock.</p>
<div class="lb-trans"><p>一些對沖基金和其他機構投資者最近對 CTSO 的持倉進行了調整。Atomi Financial Group Inc. 在第三季度收購了 Cytosorbents 的新頭寸，價值 51,000 美元。Geode Capital Management LLC 在第三季度增加了對 Cytosorbents 股票的持股，增幅為 7.5%。Geode Capital Management LLC 目前擁有 467,058 股該醫療研究公司的股票，價值 701,000 美元，此前在上個季度又購買了 32,415 股。最後，Sargent Investment Group LLC 在第二季度將其在 Cytosorbents 股票中的持倉提高了 4.9%。Sargent Investment Group LLC 目前擁有 1,433,500 股該醫療研究公司的股票，價值 1,008,000 美元，此前在上個季度又購買了 67,181 股。對沖基金和其他機構投資者持有該公司 32.87% 的股票。</p>
</div><h2>Cytosorbents Company Profile</h2>
<div class="lb-trans"><h2>Cytosorbents 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(獲取免費報告)</p>
</div><p>Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.</p>
<div class="lb-trans"><p>Cytosorbents Corporation 從事醫療設備的研究、開發和商業化，其血液淨化技術平台結合了專有的吸附劑和多孔聚合物技術，業務遍及美國、德國及國際市場。其旗艦產品為 CytoSorb，一種用於膿毒症治療的體外細胞因子吸附器，作為輔助治療，適用於其他重症護理應用、預防和治療圍手術期併發症，以及維持或增強從供體處採集的實質器官的質量以進行器官移植；並提供 VetResQ，一種用於動物膿毒症、胰腺炎和其他危重疾病的輔助治療設備。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than Cytosorbents</li>
<li>Why Invest in High-Yield Dividend Stocks?</li>
<li>Quantum Opportunity: Skywater Technology's Long-Term Potential</li>
<li>Health Care Stocks Explained: Why You Might Want to Invest</li>
<li>Nebius Group: The Rising Star in AI Infrastructure</li>
<li>3 Ways To Invest In Coffee, Other Than Drinking It</li>
<li>MarketBeat Week in Review – 12/30 - 1/03</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Cytosorbents</li>
<li>為什麼投資高收益分紅股票？</li>
<li>量子機會：Skywater Technology 的長期潛力</li>
<li>醫療保健股票解析：為什麼你可能想要投資</li>
<li>Nebius Group：人工智能基礎設施的新星</li>
<li>除了喝咖啡，還有 3 種投資咖啡的方法</li>
<li>MarketBeat 週迴顧 – 12/30 - 1/03</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和來自 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送郵件至 contact@marketbeat.com.</em></p>
</div><p>→ Trump’s Sending THIS Crypto Higher on Purpose (From Crypto 101 Media)(Ad)</p>
<div class="lb-trans"><p>→ 特朗普故意推動此加密貨幣上漲（來自 Crypto 101 Media）（廣告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMTA4Ng" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=11086&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Cytosorbents right now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Cytosorbents 嗎？</h2>
</div><p>Before you consider Cytosorbents, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Cytosorbents 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cytosorbents wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前立即購買……而 Cytosorbents 並不在名單上。</p>
</div><p>While Cytosorbents currently has a &#34;Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Cytosorbents 目前在分析師中有 “買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Cytosorbents（納斯達克代碼：CTSO）被 StockNews.com 的分析師給予持有評級